CAS 6108-05-0|Lidocaine HCl
Introduction：Basic information about CAS 6108-05-0|Lidocaine HCl, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Lidocaine HCl | ||
|---|---|---|---|
| CAS Number | 6108-05-0 | Molecular Weight | 288.814 |
| Density | / | Boiling Point | 350.8ºC at 760 mmHg |
| Molecular Formula | C14H25ClN2O2 | Melting Point | 68.5ºC |
| MSDS | ChineseUSA | Flash Point | 166ºC |
| Symbol | GHS06 | Signal Word | Danger |
Names
| Name | lidocaine hydrochloride monohydrate |
|---|---|
| Synonym | More Synonyms |
Lidocaine HCl BiologicalActivity
| Description | Lidocaine hydrochloride hydrate (Lignocaine hydrochloride hydrate) inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride hydrate decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride hydrate is an amide derivative and has potential for the research of ventricular arrhythmia[1][2]. |
|---|---|
| Related Catalog | Signaling Pathways >>Membrane Transporter/Ion Channel >>Sodium ChannelSignaling Pathways >>Apoptosis >>ApoptosisResearch Areas >>CancerSignaling Pathways >>MAPK/ERK Pathway >>MEKResearch Areas >>Cardiovascular DiseaseSignaling Pathways >>MAPK/ERK Pathway >>ERKSignaling Pathways >>Stem Cell/Wnt >>ERK |
| Target | ERK NF-κB MEK |
| In Vitro | Lidocaine (Lignocaine) (10 nM; 48 hours) decreases significantly cell proliferation[2]. Lidocaine (1-10 nM; 24-72 hours) inhibits cell viability and achieves the most suppressing effects at the concentration of 10 nM and treatment time 48 hours[2]. Lidocaine (10 nM; 48 hours) increases significantly the apoptotic cell rate[2]. Lidocaine (10 nM; 48 hours) down-regulates Cyclin D1 and up-regulates p21 expression significantly[2]. Cell Proliferation Assay[2] Cell Line: The human gastric cancer cell line MKN45 Concentration: 10 nM Incubation Time: 48 hours Result: Decreased significantly cell proliferation. Cell Viability Assay[2] Cell Line: The human gastric cancer cell line MKN45 Concentration: 1, 5 and 10 nM Incubation Time: 24, 48, 72 hours Result: Inhibited MKN45 cell viability. Apoptosis Analysis[2] Cell Line: The human gastric cancer cell line MKN45 Concentration: 10 nM Incubation Time: 48 hours Result: Increased significantly the apoptotic cell rate. Western Blot Analysis[2] Cell Line: The human gastric cancer cell line MKN45 Concentration: 10 nM Incubation Time: 48 hours Result: Down-regulated Cyclin D1 and up-regulated p21 expression significantly. |
| In Vivo | Lidocaine (Lignocaine) causes completely reversible tail nerve block in rats. Mechanical nociception block produced by lidocaine has slower onset and faster recovery compared with thermal nociception block[3]. |
| References | [1]. Cummins TR, et al. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels. J Physiol. 2007 Jul 1;582(Pt 1):11. [2]. Sui H, et al. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19(1):233. [3]. Li Z, et al. Evaluation of the antinociceptive effects of lidocaine and bupivacaine on the tail nerves of healthy rats. Basic Clin Pharmacol Toxicol. 2013 Jul;113(1):31-6. |
Chemical & Physical Properties
| Boiling Point | 350.8ºC at 760 mmHg |
|---|---|
| Melting Point | 68.5ºC |
| Molecular Formula | C14H25ClN2O2 |
| Molecular Weight | 288.814 |
| Flash Point | 166ºC |
| Exact Mass | 288.160461 |
| PSA | 41.57000 |
| LogP | 3.39440 |
| InChIKey | YECIFGHRMFEPJK-UHFFFAOYSA-N |
| SMILES | CCN(CC)CC(=O)Nc1c(C)cccc1C.Cl.O |
| Water Solubility | H2O: soluble |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 292 mg/kg
- TOXIC EFFECTS :
- Behavioral - convulsions or effect on seizure threshold
- REFERENCE :
- JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 179,580,1971
Safety Information
| Symbol | GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301 |
| Precautionary Statements | P301 + P310 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
| Hazard Codes | Xn: Harmful; |
| Risk Phrases | 22 |
| Safety Phrases | 36 |
| RIDADR | UN 2811 6 |
| WGK Germany | 3 |
| RTECS | AN7700000 |
| HS Code | 2924299090 |
Customs
| HS Code | 2924299090 |
|---|---|
| Summary | 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
Articles131
More Articles| Development and in vitro evaluation of a buccal drug delivery system based on preactivated thiolated pectin. Drug Dev. Ind. Pharm. 40(11) , 1530-7, (2014) The aim of this study was to evaluate the potential of preactivated thiolated pectin (Pec-Cys-MNA) for buccal drug delivery. Therefore, a gel formulation containing this novel polymer and the model dr... | |
| Evaluation of regional limb perfusion with chloramphenicol using the saphenous or cephalic vein in standing horses. J. Vet. Pharmacol. Ther. 38(1) , 35-40, (2015) Regional limb perfusion (RLP) significantly decreases morbidity and mortality associated with distal limb injuries in horses. There is an urgent need for finding additional effective antimicrobial dru... | |
| Intravenous lidocaine decreases tumor necrosis factor alpha expression both locally and systemically in pigs undergoing lung resection surgery. Anesth. Analg. 119(4) , 815-28, (2014) Lung resection surgery is associated with an inflammatory reaction. The use of 1-lung ventilation (OLV) seems to increase the likelihood of this reaction. Different prophylactic and therapeutic measur... |
Synonyms
| 2-(diéthylamino)-N-(2,6-diméthylphényl)acétamide chlorhydrate hydrate |
| Xyloneural |
| MFCD00150329 |
| 2-(Diethylamino)-2',6'-acetoxylidide Hydrochloride Hydrate |
| Lidocaine Hydrochloride Monohydrate |
| Lidocaine hydrochloride anhydrous |
| 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide hydrochloride hydrate |
| 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamidhydrochloridhydrat |
| Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, hydrochloride, hydrate (1:1:1) |
| EINECS 200-803-8 |
| Xylocard |
| N-(2,6-Dimethylphenyl)-N,N-diethylglycinamide hydrochloride hydrate |
| Linocaine hydrochloride |
| 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide Monohydrochloride Monohydrate |
| Lidocaine HCl |
